CanSino Biologics' Preliminary Figures Show Return to Profit in 2025; Shares Up 6%

MT Newswires Live

Feb 27

CanSino Biologics (HKG:6185) said it expects to return to profit in 2025 based on a preliminary estimate, according to a Hong Kong bourse filing Thursday.

The vaccine maker's shares were up nearly 6% in midday trade Friday.

The firm posted 27.9 million yuan in attributable profit for the year, compared with a loss of 378.9 million yuan in 2024, according to preliminary figures.

Basic earnings per share were 0.11 yuan, compared with loss per share of 1.53 yuan a year ago.

Revenue jumped 26% year-on-year to 1.07 billion yuan, the firm said, citing the preliminary data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614885894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614885894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614885894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614885894","market":"fut","top_or_hot":-1,"title":"CanSino Biologics' Preliminary Figures Show Return to Profit in 2025; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> CanSino Biologics (HKG:6185) said it expects to return to profit in 2025 based on a preliminary estimate, according to a Hong Kong bourse filing Thursday.</p><p>The vaccine maker's shares were up nearly 6% in midday trade Friday.</p><p>The firm posted 27.9 million yuan in attributable profit for the year, compared with a loss of 378.9 million yuan in 2024, according to preliminary figures.</p><p>Basic earnings per share were 0.11 yuan, compared with loss per share of 1.53 yuan a year ago.</p><p>Revenue jumped 26% year-on-year to 1.07 billion yuan, the firm said, citing the preliminary data.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics' Preliminary Figures Show Return to Profit in 2025; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics' Preliminary Figures Show Return to Profit in 2025; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CanSino Biologics (HKG:6185) said it expects to return to profit in 2025 based on a preliminary estimate, according to a Hong Kong bourse filing Thursday.</p><p>The vaccine maker's shares were up nearly 6% in midday trade Friday.</p><p>The firm posted 27.9 million yuan in attributable profit for the year, compared with a loss of 378.9 million yuan in 2024, according to preliminary figures.</p><p>Basic earnings per share were 0.11 yuan, compared with loss per share of 1.53 yuan a year ago.</p><p>Revenue jumped 26% year-on-year to 1.07 billion yuan, the firm said, citing the preliminary data.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614885894","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614885894","pubTimestamp":1772171138,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CanSino Biologics  said it expects to return to profit in 2025 based on a preliminary estimate, according to a Hong Kong bourse filing Thursday.The vaccine maker's shares were up nearly 6% in midday trade Friday.The firm posted 27.9 million yuan in attributable profit for the year, compared with a loss of 378.9 million yuan in 2024, according to preliminary figures.Basic earnings per share were 0.11 yuan, compared with loss per share of 1.53 yuan a year ago.Revenue jumped 26% year-on-year to 1.07 billion yuan, the firm said, citing the preliminary data.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","06185":"康希诺生物","BK1161":"生物科技","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"康希诺生物的初步数据显示2025年将恢复盈利；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics (HKG:6185) said it expects to return to profit in 2025 based on a preliminary estimate, according to a Hong Kong bourse filing Thursday.The vaccine maker's shares were up nearly 6% in midday trade Friday.The firm posted 27.9 million yuan in attributable profit for the year, compared with a loss of 378.9 million yuan in 2024, according to preliminary figures.Basic earnings per share were 0.11 yuan, compared with loss per share of 1.53 yuan a year ago.Revenue jumped 26% year-on-year to 1.07 billion yuan, the firm said, citing the preliminary data.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}